Literature DB >> 19877007

Antigen-specific Treg impair CD8(+) T-cell priming by blocking early T-cell expansion.

Pascal Chappert1, Marylène Leboeuf, Philippe Rameau, Mélanie Lalfer, Sabine Desbois, Roland S Liblau, Olivier Danos, Jean M Davoust, David-Alexandre Gross.   

Abstract

Foxp3(+) Treg are crucial for the maintenance of self-tolerance and have been shown to control CD8(+) T-cell effector functions. In addition, Treg are thought to control the priming of CD8(+) T cells, which recognize the same antigens as Treg. Taking advantage of our model of peripheral tolerance induction to influenza hemagglutinin (HA) after HA gene transfer, we found that HA-specific Treg suppress antigen-linked CTL responses through early blockade of CD8(+) T-cell expansion. Confronted with their cognate antigen, Treg expand more rapidly than CD8(+) T cells and are highly suppressive only during the initial stages of immune priming. They nullify HA-specific CD8(+) T-cell responses, local inflammatory responses and rejection of HA transduced cells. When HA gene transfer is performed with extensive tissue inflammation, HA-specific Treg are less effective but still reduce the frequency of newly primed HA-specific CD8(+) T cells and the ensuing frequency of memory CD8(+) T cells. Our results demonstrate that Treg control CTL priming in an antigen-specific manner at the level of T-cell expansion, highlighting how self-reactive Treg could prevent the induction of autoimmune responses through selective blockade of autoreactive T-cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19877007     DOI: 10.1002/eji.200839107

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  15 in total

1.  WT1 peptide vaccination in a CML patient: induction of effective cytotoxic T lymphocytes and significance of peptide administration interval.

Authors:  Anri Saitoh; Miwako Narita; Norihiro Watanabe; Nozomi Tochiki; Akie Yamahira; Takeshi Nakamura; Masami Kaji; Masayoshi Masuko; Tatsuo Furukawa; Ken Toba; Ichiro Fuse; Yoshifusa Aizawa; Masuhiro Takahashi
Journal:  Med Oncol       Date:  2010-01-27       Impact factor: 3.064

2.  CD4+CD25+ regulatory T cells control CD8+ T-cell effector differentiation by modulating IL-2 homeostasis.

Authors:  Alice McNally; Geoffrey R Hill; Tim Sparwasser; Ranjeny Thomas; Raymond J Steptoe
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-18       Impact factor: 11.205

3.  IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice.

Authors:  C Jackaman; D E Dye; D J Nelson
Journal:  Age (Dordr)       Date:  2014-04-19

4.  Inhibiting CXCR3-dependent CD8+ T cell trafficking enhances tolerance induction in a mouse model of lung rejection.

Authors:  Edward Seung; Josalyn L Cho; Tim Sparwasser; Benjamin D Medoff; Andrew D Luster
Journal:  J Immunol       Date:  2011-05-09       Impact factor: 5.422

5.  Inhibitory function of Tregs via soluble FGL2 in chronic hepatitis B.

Authors:  Li Xu; Daofeng Yang; Yanlin Liu; Di Wu; Xiaojing Wang; Qin Ning
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-08-11

6.  Higher Frequency and Increased Expression of Molecules Associated with Suppression on T Regulatory Cells from Newborn Compared with Adult Nonhuman Primates.

Authors:  Beth C Holbrook; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2020-09-02       Impact factor: 5.422

Review 7.  Oncolytic virotherapy reverses the immunosuppressive tumor microenvironment and its potential in combination with immunotherapy.

Authors:  Yalei Zhang; Ye Li; Kun Chen; Ling Qian; Peng Wang
Journal:  Cancer Cell Int       Date:  2021-05-13       Impact factor: 5.722

8.  Methodology for Anti-Gene Anti-IGF-I Therapy of Malignant Tumours.

Authors:  Jerzy Trojan; Yuexin X Pan; Ming X Wei; Adama Ly; Alexander Shevelev; Maciej Bierwagen; Marie-Yvonne Ardourel; Ladislas A Trojan; Alvaro Alvarez; Christian Andres; Maria C Noguera; Ignacio Briceno; Beatriz H Aristizabal; Heliodor Kasprzak; Huynh T Duc; Donald D Anthony
Journal:  Chemother Res Pract       Date:  2012-02-14

Review 9.  Balancing Immune Protection and Immune Pathology by CD8(+) T-Cell Responses to Influenza Infection.

Authors:  Susu Duan; Paul G Thomas
Journal:  Front Immunol       Date:  2016-02-05       Impact factor: 7.561

10.  Anti-Interleukin-6 Promotes Allogeneic Bone Marrow Engraftment and Prolonged Graft Survival in an Irradiation-Free Murine Transplant Model.

Authors:  Nicolas Granofszky; Andreas M Farkas; Moritz Muckenhuber; Benedikt Mahr; Lukas Unger; Svenja Maschke; Nina Pilat; Raimund Holly; Mario Wiletel; Heinz Regele; Thomas Wekerle
Journal:  Front Immunol       Date:  2017-07-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.